Protein Degradation & Targeting Undruggables Europe 2023

Facilitate successful clinical translation of PROTACs and Molecular Glues by expanding target classes and the ligase landscape through rational discovery & design paradigms beyond oncology

Download the full event programme
Basel, Switzerland
19-20 September, 2023

“A lot of data on PROTAC research has been disclosed at this event. And also, many leaders in PROTACs shared their experience and concerns about their development. Many start-up companies also delivered their progress. We are able to discuss future directions as well as difficulties with experts from both industry and the academic area and learned a lot.”

Yuqing Huang Suzhou, Kintor Pharmaceuticals

Welcome to Protein Degradation & Targeting Undruggables Congress Europe

Join leading experts & researchers from pharma, biotech and academic research institutions at the most established European event for undruggable drug discovery.

Across two comprehensive days, deep dive sessions allow you to explore cutting-edge advancements in targeted protein degradation, address challenges in discovering ligases & ligands, ensure safety of PROTACs and leverage induced proximity concepts. With more opportunities to build partnerships than ever before through roundtables, workshops and 1-2-1 meeting opportunities, it provides an unmissable chance to optimize your research outcomes, pipeline viability and therapeutic success across diverse indications. 

40+
Leading Speakers
200+
Attendees
4+
Hours of Panel Discussions & Roundtables
6+
Networking Hours

Meet the speakers

 

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer
 

Gwenn Hansen

Chief Scientific Officer
Nurix Therapeutics

Gwenn Hansen

Chief Scientific Officer
Nurix Therapeutics

Gwenn Hansen

Chief Scientific Officer
Nurix Therapeutics
 

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics
 

Luc Brunsveld

Co-Founder
Ambagon Therapeutics

Luc Brunsveld

Co-Founder
Ambagon Therapeutics

Luc Brunsveld

Co-Founder
Ambagon Therapeutics
 

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl is a director in Oncology Research in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. Presently, his team focuses on targeted protein degradation in cancer cell signaling.

Before 2010, he worked at the German Cancer Research Center in Heidelberg, Germany. He has worked at several small biotech companies in Heidelberg, including Phenex Pharmaceuticals. Manfred Koegl studied biology in Vienna and received his PhD in cell biology in 1994 at the EMBL, Heidelberg.

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl

Director of Oncology Research
Boehringer Ingelheim

Manfred Koegl is a director in Oncology Research in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. Presently, his team focuses on targeted protein degradation in cancer cell signaling.

Before 2010, he worked at the German Cancer Research Center in Heidelberg, Germany. He has worked at several small biotech companies in Heidelberg, including Phenex Pharmaceuticals. Manfred Koegl studied biology in Vienna and received his PhD in cell biology in 1994 at the EMBL, Heidelberg.

 

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis

Greg Hollingworth

Director, New Modalities & TPD Global Initiatives Co-Lead
Novartis
 

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca
 

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph
 

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences

Ted Suh

VP, Chemistry
Orionis Biosciences
 

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics
 

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio.

Hyunsun Jo

CEO
Pin Therapeutics

Hyunsun Jo

CEO
Pin Therapeutics

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).

 

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech
 

Matthias Brand

Co-Founder & CSO
Proxygen

Matthias Brand

Co-Founder & CSO
Proxygen

Matthias Brand

Co-Founder & CSO
Proxygen
 

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS
 

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute
 

Merve Mutlu

Postdoctoral Scholar
Novartis

Merve Mutlu

Postdoctoral Scholar
Novartis

Merve Mutlu

Postdoctoral Scholar
Novartis
 

Martin Hemmerling

Principal Scientist
AstraZeneca

Martin Hemmerling

Principal Scientist
AstraZeneca

Martin Hemmerling

Principal Scientist
AstraZeneca
 

Jacob Aguirre

Postdoctoral Researcher
Friedrich Miescher Institute

Jacob Aguirre

Postdoctoral Researcher
Friedrich Miescher Institute

Jacob Aguirre

Postdoctoral Researcher
Friedrich Miescher Institute
 

Benedict Cross

Chief Technology Officer
Phoremost

Benedict Cross

Chief Technology Officer
Phoremost

Benedict Cross

Chief Technology Officer
Phoremost
 

Fiona Sorrell

Principal Scientist, Medicinal Chemistry
Merck KGaA

Fiona Sorrell

Principal Scientist, Medicinal Chemistry
Merck KGaA

Fiona Sorrell

Principal Scientist, Medicinal Chemistry
Merck KGaA
 

Konstantinos Tzelepis

Principal Investigator
Wellcome-MRC Cambridge Stem Cell Institute/University of Cambridge

Konstantinos Tzelepis

Principal Investigator
Wellcome-MRC Cambridge Stem Cell Institute/University of Cambridge

Konstantinos Tzelepis

Principal Investigator
Wellcome-MRC Cambridge Stem Cell Institute/University of Cambridge
 

Dennis Gillingham

Professor
University of Basel

Dennis Gillingham

Professor
University of Basel

Dennis Gillingham

Professor
University of Basel
 

Axel Vicart

Director of Mechanistic Safety
Novartis

Axel Vicart

Director of Mechanistic Safety
Novartis

Axel Vicart

Director of Mechanistic Safety
Novartis
 

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist
Roche

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist
Roche

Caroline Rynn

DMPK-PD Project Leader, Senior Principal Scientist
Roche
 

Steven Edenson

Strategic Collaborations Manager
Promega

Steven Edenson

Strategic Collaborations Manager
Promega

Steven Edenson

Strategic Collaborations Manager
Promega
 

Ingrid Wertz

CEO & Co-Founder
Lyterian Therapeutics

Ingrid Wertz

CEO & Co-Founder
Lyterian Therapeutics

Ingrid Wertz

CEO & Co-Founder
Lyterian Therapeutics
 

Katelyn Cassidy

UPS Biology, Proteomics Scientist
C4 Therapeutics

Katelyn Cassidy

UPS Biology, Proteomics Scientist
C4 Therapeutics

Katelyn Cassidy

UPS Biology, Proteomics Scientist
C4 Therapeutics
 

Thomas Geiger

Scientist
TU Darmstadt

Thomas Geiger

Scientist
TU Darmstadt

Thomas Geiger

Scientist
TU Darmstadt
 

Renato Alves

Project Advisor
Pelago Bioscience

Renato Alves

Project Advisor
Pelago Bioscience

Renato Alves

Project Advisor
Pelago Bioscience
 

Patrick Gunning

Chief Innovation Officer & Co-Founder
Dunad Therapeutics

Patrick Gunning

Chief Innovation Officer & Co-Founder
Dunad Therapeutics

Patrick Gunning

Chief Innovation Officer & Co-Founder
Dunad Therapeutics
 

Magnus Walter

Senior Vice President, Chemical Sciences
Monte Rosa Therapeutics

Magnus Walter

Senior Vice President, Chemical Sciences
Monte Rosa Therapeutics

Magnus Walter

Senior Vice President, Chemical Sciences
Monte Rosa Therapeutics
 

Kwok Ho Chan

Investigator
GSK

Kwok Ho Chan

Investigator
GSK

Kwok Ho Chan

Investigator
GSK
 

Malik Muller

Head of Scientific Operations
Biognosys

Malik Muller

Head of Scientific Operations
Biognosys

Malik Muller

Head of Scientific Operations
Biognosys
 

Axel Vicart

Director of Mechanistic Safety
Novartis

Axel Vicart

Director of Mechanistic Safety
Novartis

Axel Vicart

Director of Mechanistic Safety
Novartis
 

Katelyn Cassidy

UPS Biology, Proteomics Scientist
C4 Therapeutics

Katelyn Cassidy

UPS Biology, Proteomics Scientist
C4 Therapeutics

Katelyn Cassidy

UPS Biology, Proteomics Scientist
C4 Therapeutics

Download the 2023 programme

View the full event programme for the Protein Degradation & Targeting Undruggables Congress Europe 2023!

What's new this year?

1) Improved Networking Opportunities

Meet your next collaborator, with a revamped programme allowing for more business-critical partnering opportunities than ever with over 8 hours of dedicated networking time

2) More Key Players

Meet the game changers from across the industry, with new companies confirmed for 2023 including Dunad, Nurix, Kymera, Abagon, Neomorph and C4 Therapeutics.

3) Business Strategy Sessions

In a market still in its infancy, its critical to gain the strategic insights you need to ensure your business thrives – and we’re bringing together the late-stage companies paving the way in Europe for Protein Degradation to share their guidance on running a robust biotech.


Download the agenda

Audience Breakdown

30%
Pharma
40%
Biotech
15%
Academic & Research Institutes
15%
Service Providers

Pharma

Biotech

Academic & Research Institutes

Service Providers

Who will you meet?

Attendee Testimonials

Delegate Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase after

— January 1, 1970 —

Preparing registration...

Become a partner

Protein Degradation & Targeting Undruggables is your global, multi-channel partner to reach, engage and interact with the most influential and important stakeholders in the world of protein degradation. With a solution to hit every objective, our high-level programmes, tailored introductions, bespoke networking and content-driven marketing offer multiple ways to engage your target market both at the event and in the run up.

Why partner with us?

⦁             Be recognized as an industry leader

⦁             Get the eyes of hundreds of decision makers on your brand

⦁             Create space for the most important conversations, and the ones you never knew were out there

⦁             Network with the protein degradation industry elite

⦁             Amplify your biggest announcements, research and expertise

 Want to know more? We’re here to help you find out all about partnership options including:

Thought Leadership: Presentations, Panel Discussions, Roundtables, Workshops

Networking: 1-1 Meetings, Breakfast Briefings, Networking Dinners, Drinks Party

Brand Awareness: Track Sponsorship, Keynote Presentation, Networking Booth

Find out more by calling us at +44 (0)20 3696 2920 or email Jack Tollervey at [email protected] 

Protein Degradation Media Kit

For more information on webinarsroundtablescontent marketing packagesinterviews and bespoke opportunities to accelerate Protein dedgradation innovation, download the Media Kit below.

DOWNLOAD THE MEDIA KIT

If you have any questions, please contact JackTollervey,  Commercial Partnerships Manager, [email protected].

2023 Partners

Platinum Sponsor

Silver Sponsors

Event Partner

Media Partners

Resources

Download Resource

Venue

Congress Center Basel Messeplatz. 21 4058, Basel

Congress Center Basel

Messeplatz. 21

4058, Basel

Highlights from previous years

Protein degradation Congress

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us